{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:30:01Z","timestamp":1792801801572,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"UNICEF\/UNDP\/World Bank\/WHO","id":[{"id":"https:\/\/ror.org\/00ae7jd04","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13071-018-2634-x","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T07:37:15Z","timestamp":1519285035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda"],"prefix":"10.1186","volume":"11","author":[{"given":"Freddie","family":"Kansiime","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seraphine","family":"Adibaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Wamboga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin","family":"Idi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Drago","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Yamuah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Vaillant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Kioy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Olliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enock","family":"Matovu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"2634_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1756-3305-1-3","volume":"1","author":"D Steverding","year":"2008","unstructured":"Steverding D. The history of African trypanosomiasis. Parasit Vectors. 2008;1:3.","journal-title":"Parasit Vectors"},{"issue":"10","key":"2634_CR2","doi-asserted-by":"publisher","first-page":"e1859","DOI":"10.1371\/journal.pntd.0001859","volume":"6","author":"P Simarro","year":"2012","unstructured":"Simarro P, Cecchi G, Franco J, Paone M, Diarra A, Ruiz-Postigo J, et al. Estimating and mapping the population at risk of sleeping sickness. PLoS Negl Trop Dis. 2012;6(10):e1859.","journal-title":"PLoS Negl Trop Dis"},{"key":"2634_CR3","unstructured":"WHO. Control and surveillance of human African trypanosomiasis. WHO Tech Rep Ser. 2013;984:1\u2013237."},{"issue":"4","key":"2634_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0035-9203(99)90151-7","volume":"93","author":"D Legros","year":"1999","unstructured":"Legros D, Evans S, Maiso F, Enyaru J, Mbulamberi D. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg. 1999;93(4):439\u201342.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"2634_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1046\/j.1365-3156.2001.00712.x","volume":"6","author":"E Matovu","year":"2001","unstructured":"Matovu E, Enyaru J, Legros D, Schmid C, Seebeck T, Kaminsky R. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Trop Med Int Health. 2001;6(5):407\u201311.","journal-title":"Trop Med Int Health"},{"issue":"5","key":"2634_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1046\/j.1365-3156.2001.00725.x","volume":"6","author":"C Burri","year":"2001","unstructured":"Burri C, Keiser J. Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop Med Int Health. 2001;6(5):412\u201320.","journal-title":"Trop Med Int Health"},{"issue":"6","key":"2634_CR7","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3201\/eid1406.071266","volume":"14","author":"J Robays","year":"2008","unstructured":"Robays J, Nyamowala G, Sese C, Kande Betu Ku Mesu V, Lutumba P, Van der Veken W, Boelaert M. High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. Emerg Infect Dis. 2008;14(6):966\u20137.","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"2634_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1046\/j.1365-3156.2001.00724.x","volume":"6","author":"A Stanghellini","year":"2001","unstructured":"Stanghellini A, Josenando T. The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health. 2001;6(5):330\u20134.","journal-title":"Trop Med Int Health"},{"issue":"5","key":"2634_CR9","doi-asserted-by":"publisher","first-page":"818","DOI":"10.2307\/3281038","volume":"69","author":"A De Gee","year":"1983","unstructured":"De Gee A, McCann P, Mansfield J. Role of antibody in the elimination of trypanosomes after DL-\u03b1-difluoromethylornithine chemotherapy. J Parasitol. 1983;69(5):818\u201322.","journal-title":"J Parasitol"},{"issue":"8","key":"2634_CR10","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1371\/journal.pctr.0010039","volume":"1","author":"G Priotto","year":"2006","unstructured":"Priotto G, Fogg C, Balasegaram M, Erphas O, Louga A, Checchi F, et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trial. 2006;1(8):e39.","journal-title":"PLoS Clin Trial"},{"issue":"9683","key":"2634_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","volume":"374","author":"G Priotto","year":"2009","unstructured":"Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009;374(9683):56\u201364.","journal-title":"Lancet"},{"key":"2634_CR12","volume-title":"19th WHO model list of essential medicines","author":"World Health Organization (WHO)","year":"2016","unstructured":"World Health Organization (WHO). 19th WHO model list of essential medicines. Geneva: WHO; 2016."},{"issue":"9213","key":"2634_CR13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/S0140-6736(00)02141-3","volume":"355","author":"C Burri","year":"2000","unstructured":"Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet. 2000;355(9213):1419\u201325.","journal-title":"Lancet"},{"issue":"11","key":"2634_CR14","first-page":"1284","volume":"78","author":"J P\u00e9pin","year":"2000","unstructured":"P\u00e9pin J, Khonde N, Maiso F, Doua F, Jaffar S, Ngampo S, et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull WHO. 2000;78(11):1284\u201395.","journal-title":"Bull WHO"},{"issue":"11","key":"2634_CR15","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1086\/522982","volume":"45","author":"G Priotto","year":"2007","unstructured":"Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Karunakara U. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis. 2007;45(11):1435\u201342.","journal-title":"Clin Infect Dis"},{"issue":"9436","key":"2634_CR16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0140-6736(04)16940-7","volume":"364","author":"C Schmid","year":"2004","unstructured":"Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet. 2004;364(9436):789\u201390.","journal-title":"Lancet"},{"issue":"4","key":"2634_CR17","first-page":"384","volume":"27","author":"P Woo","year":"1970","unstructured":"Woo P. The haematocrit centrifuge technique for the diagnosis of African trypanosomiasis. Acta Trop. 1970;27(4):384\u20136.","journal-title":"Acta Trop"},{"key":"2634_CR18","doi-asserted-by":"crossref","unstructured":"B\u00fcscher P, Ngoyi DM, Kabor\u00e9 J, Lejon V, Robays J. Jamonneau V, et al. Improved models of mini anion exchange centrifugation technique (mAECT) and modified single centrifugation (MSC) for sleeping sickness diagnosis and staging. PLoS Negl Trop Dis. 2009;3(11):e471.","DOI":"10.1371\/journal.pntd.0000471"},{"issue":"6","key":"2634_CR19","first-page":"553","volume":"76","author":"V Lejon","year":"1998","unstructured":"Lejon V, B\u00fcscher P, Sema N, Magnus E, Van Meirvenne N. Human African trypanosomiasis: a latex agglutination field test for quantifying IgM in cerebrospinal fluid. Bull WHO. 1998;76(6):553.","journal-title":"Bull WHO"},{"key":"2634_CR20","unstructured":"NCI-CTEP-NIH. National Cancer Institute: Cancer therapy evaluation program. Common terminology criteria for adverse events, version 4, 1999. \n                    https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_40\n                    \n                  . Accessed 16 Jan 2017."},{"key":"2634_CR21","volume-title":"Recommendations of the informal consultation on issues for clinical product development for human African trypanosomiasis","author":"World Health Organization","year":"2007","unstructured":"World Health Organization. Recommendations of the informal consultation on issues for clinical product development for human African trypanosomiasis. Geneva: WHO; 2007."},{"issue":"2","key":"2634_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/cid\/cis886","volume":"56","author":"E Alirol","year":"2013","unstructured":"Alirol E, Schrumpf D, Amici Heradi J, Riedel A, de Patoul C, Quere M, Chappuis F. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: M\u00e9decins Sans Fronti\u00e8res experience in the Democratic Republic of the Congo. Clin Infect Dis. 2013;56(2):195\u2013203.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2634_CR23","doi-asserted-by":"publisher","first-page":"e1920","DOI":"10.1371\/journal.pntd.0001920","volume":"6","author":"C Schmid","year":"2012","unstructured":"Schmid C, Kuemmerle A, Blum J, Ghabri S, Kande V, Mutombo W, et al. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. PLoS Negl Trop Dis. 2012;6(11):e1920.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"2634_CR24","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1371\/journal.pntd.0000064","volume":"1","author":"F Checchi","year":"2007","unstructured":"Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, Priotto G. Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis. 2007;1(2):e64.","journal-title":"PLoS Negl Trop Dis"},{"key":"2634_CR25","first-page":"CD006201","volume":"6","author":"V Lutje","year":"2013","unstructured":"Lutje V, Seixas J, Kennedy A. Chemotherapy for second-stage human African trypanosomiasis. Cochrane Database Syst Rev. 2013;6:CD006201.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2634_CR26","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1586\/14787210.2014.959496","volume":"12","author":"G Eperon","year":"2014","unstructured":"Eperon G, Balasegaram M, Potet J, Mowbray C, Valverde O, Chappuis F. Treatment options for second-stage gambiense human African trypanosomiasis. Expert Rev Anti-Infect Ther. 2014;12(11):1407\u201317.","journal-title":"Expert Rev Anti-Infect Ther"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-018-2634-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T19:29:47Z","timestamp":1550777387000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-018-2634-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2634"],"URL":"https:\/\/doi.org\/10.1186\/s13071-018-2634-x","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]},"assertion":[{"value":"20 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the WHO Ethics Review Committee, the National Ethics Committee of the Uganda Ministry of Health and the Uganda National Council for Science and Technology. All participants gave written informed consent and an independent data safety and monitoring board reviewed the study regularly.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"105"}}